Shopping Cart 0
Cart Subtotal
USD 0

Hemostasis Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Hemostasis Rapid Tests & Point of Care (POC)-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Hemostasis Rapid Tests & Point of Care (POC)-Medical Devices Pipeline Assessment, 2018" provides an overview of Hemostasis Rapid Tests & Point of Care (POC) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hemostasis Rapid Tests & Point of Care (POC) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Hemostasis Rapid Tests & Point of Care (POC) under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Hemostasis Rapid Tests & Point of Care (POC) and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry.

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Hemostasis Rapid Tests & Point of Care (POC) under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 4

2 Introduction 5

2.1 Hemostasis Rapid Tests & Point of Care (POC) Overview 5

3 Products under Development 6

3.1 Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Stage of Development 6

3.2 Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Segment 7

3.3 Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Territory 8

3.4 Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Regulatory Path 9

3.5 Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Estimated Approval Date 10

4 Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products under Development by Companies 11

4.1 Hemostasis Rapid Tests & Point of Care (POC) Companies-Pipeline Products by Stage of Development 11

4.2 Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Stage of Development 12

5 Hemostasis Rapid Tests & Point of Care (POC) Companies and Product Overview 13

5.1 Alere Inc Company Overview 13

5.1.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 13

5.2 Atomo Diagnostics Pty Limited Company Overview 14

5.2.1 Atomo Diagnostics Pty Limited Pipeline Products & Ongoing Clinical Trials Overview 14

5.3 Carclo Diagnostic Solutions Ltd Company Overview 15

5.3.1 Carclo Diagnostic Solutions Ltd Pipeline Products & Ongoing Clinical Trials Overview 15

5.4 Cascade Metrix LLC Company Overview 16

5.4.1 Cascade Metrix LLC Pipeline Products & Ongoing Clinical Trials Overview 16

5.5 Edan Instruments Inc Company Overview 17

5.5.1 Edan Instruments Inc Pipeline Products & Ongoing Clinical Trials Overview 17

5.6 EKF Diagnostics Holdings Plc Company Overview 18

5.6.1 EKF Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview 18

5.7 Helena Laboratories Corp Company Overview 19

5.7.1 Helena Laboratories Corp Pipeline Products & Ongoing Clinical Trials Overview 19

5.8 Radiometer Medical ApS Company Overview 27

5.8.1 Radiometer Medical ApS Pipeline Products & Ongoing Clinical Trials Overview 27

5.9 Universal Biosensors Inc Company Overview 29

5.9.1 Universal Biosensors Inc Pipeline Products & Ongoing Clinical Trials Overview 29

6 Hemostasis Rapid Tests & Point of Care (POC)- Recent Developments 30

6.1 Jun 14, 2018: EMOSIS Announces an Exclusive Distribution Agreement with 5-Diagnostics and the Start of Commercialization 30

6.2 Mar 20, 2018: EMOSIS Announces CE Mark Approval for HIT Confirm Kit 30

6.3 Sep 29, 2017: Alere Announces the U.S. Department of Justice Closes Investigation 31

6.4 Sep 28, 2017: Alere Announces Settlement with SEC 31

6.5 Aug 03, 2017: Alere Reports Second Quarter 2017 Financial Results 31

7 Appendix 33

7.1 Methodology 33

7.2 About GlobalData 36

7.3 Contact Us 36

7.4 Disclaimer 36


List Of Figure

1.2 List of Figures

Figure 1: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Stage of Development 6

Figure 2: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Segment 7

Figure 3: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Territory 8

Figure 4: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Regulatory Path 9

Figure 5: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Estimated Approval Date 10


List Of Table

1.1 List of Tables

Table 1: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Stage of Development 6

Table 2: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Segment 7

Table 3: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Territory 8

Table 4: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Regulatory Path 9

Table 5: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Estimated Approval Date 10

Table 6: Hemostasis Rapid Tests & Point of Care (POC) Companies-Pipeline Products by Stage of Development 11

Table 7: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Stage of Development 12

Table 8: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 13

Table 9: Afinion PT Test-Capillary Blood-Product Status 13

Table 10: Afinion PT Test-Capillary Blood-Product Description 13

Table 11: Atomo Diagnostics Pty Limited Pipeline Products & Ongoing Clinical Trials Overview 14

Table 12: AtomoRapid-Coagulation Monitoring-Product Status 14

Table 13: AtomoRapid-Coagulation Monitoring-Product Description 14

Table 14: Carclo Diagnostic Solutions Ltd Pipeline Products & Ongoing Clinical Trials Overview 15

Table 15: Micropoc-CAT-Haemostasis Assay-Product Status 15

Table 16: Micropoc-CAT-Haemostasis Assay-Product Description 15

Table 17: Cascade Metrix LLC Pipeline Products & Ongoing Clinical Trials Overview 16

Table 18: Multiple Blood Analytes Test-Product Status 16

Table 19: Multiple Blood Analytes Test-Product Description 16

Table 20: Edan Instruments Inc Pipeline Products & Ongoing Clinical Trials Overview 17

Table 21: i15-Coagulation Test-Product Status 17

Table 22: i15-Coagulation Test-Product Description 17

Table 23: EKF Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview 18

Table 24: Point-Of-Care Test-Coagulation-Product Status 18

Table 25: Point-Of-Care Test-Coagulation-Product Description 18

Table 26: Helena Laboratories Corp Pipeline Products & Ongoing Clinical Trials Overview 19

Table 27: Cascade Abrazo-Activated Partial Thromboplastin Time (aPTT)-Product Status 19

Table 28: Cascade Abrazo-Activated Partial Thromboplastin Time (aPTT)-Product Description 20

Table 29: Cascade Abrazo-c-ACT-Product Status 20

Table 30: Cascade Abrazo-c-ACT-Product Description 20

Table 31: Cascade Abrazo-c-ACT-LR-Product Status 21

Table 32: Cascade Abrazo-c-ACT-LR-Product Description 21

Table 33: Cascade Abrazo-Direct Oral Anticoagulants Test-Product Status 21

Table 34: Cascade Abrazo-Direct Oral Anticoagulants Test-Product Description 22

Table 35: Cascade Abrazo-Direct Thrombin Inhibitors-Product Status 22

Table 36: Cascade Abrazo-Direct Thrombin Inhibitors-Product Description 22

Table 37: Cascade Abrazo-Fibrinogen-Product Status 23

Table 38: Cascade Abrazo-Fibrinogen-Product Description 23

Table 39: Cascade Abrazo-Heparin Titration-Product Status 23

Table 40: Cascade Abrazo-Heparin Titration-Product Description 24

Table 41: Cascade Abrazo-LMWH-Product Status 24

Table 42: Cascade Abrazo-LMWH-Product Description 24

Table 43: Cascade Abrazo-Protamine Titration-Product Status 25

Table 44: Cascade Abrazo-Protamine Titration-Product Description 25

Table 45: Cascade Abrazo-PT-C-Product Status 25

Table 46: Cascade Abrazo-PT-C-Product Description 26

Table 47: Radiometer Medical ApS Pipeline Products & Ongoing Clinical Trials Overview 27

Table 48: AQT90 FLEX-APTT Test-Product Status 27

Table 49: AQT90 FLEX-APTT Test-Product Description 27

Table 50: AQT90 FLEX-PT-INR Test-Product Status 28

Table 51: AQT90 FLEX-PT-INR Test-Product Description 28

Table 52: Universal Biosensors Inc Pipeline Products & Ongoing Clinical Trials Overview 29

Table 53: Diagnostic Assay-Coagulation-Product Status 29

Table 54: Diagnostic Assay-Coagulation-Product Description 29

Table 55: Glossary 35

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Alere Inc, Afinion PT Test - Capillary Blood; Atomo Diagnostics Pty Limited, AtomoRapid - Coagulation Monitoring; Carclo Diagnostic Solutions Ltd, Micropoc-CAT - Haemostasis Assay; Cascade Metrix LLC, Multiple Blood Analytes Test; Edan Instruments Inc, i15 - Coagulation Test; EKF Diagnostics Holdings Plc, Point-Of-Care Test - Coagulation; Helena Laboratories Corp, Cascade Abrazo - Activated Partial Thromboplastin Time (aPTT); Helena Laboratories Corp, Cascade Abrazo - c-ACT; Helena Laboratories Corp, Cascade Abrazo - c-ACT-LR; Helena Laboratories Corp, Cascade Abrazo - Direct Oral Anticoagulants Test; Helena Laboratories Corp, Cascade Abrazo - Direct Thrombin Inhibitors; Helena Laboratories Corp, Cascade Abrazo - Fibrinogen; Helena Laboratories Corp, Cascade Abrazo - Heparin Titration; Helena Laboratories Corp, Cascade Abrazo - LMWH; Helena Laboratories Corp, Cascade Abrazo - Protamine Titration; Helena Laboratories Corp, Cascade Abrazo - PT-C; Radiometer Medical ApS, AQT90 FLEX - APTT Test; Radiometer Medical ApS, AQT90 FLEX - PT-INR Test; Universal Biosensors Inc, Diagnostic Assay - Coagulation


Companies

Alere Inc

Atomo Diagnostics Pty Limited

Carclo Diagnostic Solutions Ltd

Cascade Metrix LLC

Edan Instruments Inc

EKF Diagnostics Holdings Plc

Helena Laboratories Corp

Radiometer Medical ApS

Universal Biosensors Inc

Hemostasis Rapid Tests & Point of Care (POC)-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Hemostasis Rapid Tests & Point of Care (POC)-Medical Devices Pipeline Assessment, 2018" provides an overview of Hemostasis Rapid Tests & Point of Care (POC) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hemostasis Rapid Tests & Point of Care (POC) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Hemostasis Rapid Tests & Point of Care (POC) under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Hemostasis Rapid Tests & Point of Care (POC) and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry.

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Hemostasis Rapid Tests & Point of Care (POC) under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date.

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 4

2 Introduction 5

2.1 Hemostasis Rapid Tests & Point of Care (POC) Overview 5

3 Products under Development 6

3.1 Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Stage of Development 6

3.2 Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Segment 7

3.3 Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Territory 8

3.4 Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Regulatory Path 9

3.5 Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Estimated Approval Date 10

4 Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products under Development by Companies 11

4.1 Hemostasis Rapid Tests & Point of Care (POC) Companies-Pipeline Products by Stage of Development 11

4.2 Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Stage of Development 12

5 Hemostasis Rapid Tests & Point of Care (POC) Companies and Product Overview 13

5.1 Alere Inc Company Overview 13

5.1.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 13

5.2 Atomo Diagnostics Pty Limited Company Overview 14

5.2.1 Atomo Diagnostics Pty Limited Pipeline Products & Ongoing Clinical Trials Overview 14

5.3 Carclo Diagnostic Solutions Ltd Company Overview 15

5.3.1 Carclo Diagnostic Solutions Ltd Pipeline Products & Ongoing Clinical Trials Overview 15

5.4 Cascade Metrix LLC Company Overview 16

5.4.1 Cascade Metrix LLC Pipeline Products & Ongoing Clinical Trials Overview 16

5.5 Edan Instruments Inc Company Overview 17

5.5.1 Edan Instruments Inc Pipeline Products & Ongoing Clinical Trials Overview 17

5.6 EKF Diagnostics Holdings Plc Company Overview 18

5.6.1 EKF Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview 18

5.7 Helena Laboratories Corp Company Overview 19

5.7.1 Helena Laboratories Corp Pipeline Products & Ongoing Clinical Trials Overview 19

5.8 Radiometer Medical ApS Company Overview 27

5.8.1 Radiometer Medical ApS Pipeline Products & Ongoing Clinical Trials Overview 27

5.9 Universal Biosensors Inc Company Overview 29

5.9.1 Universal Biosensors Inc Pipeline Products & Ongoing Clinical Trials Overview 29

6 Hemostasis Rapid Tests & Point of Care (POC)- Recent Developments 30

6.1 Jun 14, 2018: EMOSIS Announces an Exclusive Distribution Agreement with 5-Diagnostics and the Start of Commercialization 30

6.2 Mar 20, 2018: EMOSIS Announces CE Mark Approval for HIT Confirm Kit 30

6.3 Sep 29, 2017: Alere Announces the U.S. Department of Justice Closes Investigation 31

6.4 Sep 28, 2017: Alere Announces Settlement with SEC 31

6.5 Aug 03, 2017: Alere Reports Second Quarter 2017 Financial Results 31

7 Appendix 33

7.1 Methodology 33

7.2 About GlobalData 36

7.3 Contact Us 36

7.4 Disclaimer 36


List Of Figure

1.2 List of Figures

Figure 1: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Stage of Development 6

Figure 2: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Segment 7

Figure 3: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Territory 8

Figure 4: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Regulatory Path 9

Figure 5: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Estimated Approval Date 10


List Of Table

1.1 List of Tables

Table 1: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Stage of Development 6

Table 2: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Segment 7

Table 3: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Territory 8

Table 4: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Regulatory Path 9

Table 5: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Estimated Approval Date 10

Table 6: Hemostasis Rapid Tests & Point of Care (POC) Companies-Pipeline Products by Stage of Development 11

Table 7: Hemostasis Rapid Tests & Point of Care (POC)-Pipeline Products by Stage of Development 12

Table 8: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 13

Table 9: Afinion PT Test-Capillary Blood-Product Status 13

Table 10: Afinion PT Test-Capillary Blood-Product Description 13

Table 11: Atomo Diagnostics Pty Limited Pipeline Products & Ongoing Clinical Trials Overview 14

Table 12: AtomoRapid-Coagulation Monitoring-Product Status 14

Table 13: AtomoRapid-Coagulation Monitoring-Product Description 14

Table 14: Carclo Diagnostic Solutions Ltd Pipeline Products & Ongoing Clinical Trials Overview 15

Table 15: Micropoc-CAT-Haemostasis Assay-Product Status 15

Table 16: Micropoc-CAT-Haemostasis Assay-Product Description 15

Table 17: Cascade Metrix LLC Pipeline Products & Ongoing Clinical Trials Overview 16

Table 18: Multiple Blood Analytes Test-Product Status 16

Table 19: Multiple Blood Analytes Test-Product Description 16

Table 20: Edan Instruments Inc Pipeline Products & Ongoing Clinical Trials Overview 17

Table 21: i15-Coagulation Test-Product Status 17

Table 22: i15-Coagulation Test-Product Description 17

Table 23: EKF Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview 18

Table 24: Point-Of-Care Test-Coagulation-Product Status 18

Table 25: Point-Of-Care Test-Coagulation-Product Description 18

Table 26: Helena Laboratories Corp Pipeline Products & Ongoing Clinical Trials Overview 19

Table 27: Cascade Abrazo-Activated Partial Thromboplastin Time (aPTT)-Product Status 19

Table 28: Cascade Abrazo-Activated Partial Thromboplastin Time (aPTT)-Product Description 20

Table 29: Cascade Abrazo-c-ACT-Product Status 20

Table 30: Cascade Abrazo-c-ACT-Product Description 20

Table 31: Cascade Abrazo-c-ACT-LR-Product Status 21

Table 32: Cascade Abrazo-c-ACT-LR-Product Description 21

Table 33: Cascade Abrazo-Direct Oral Anticoagulants Test-Product Status 21

Table 34: Cascade Abrazo-Direct Oral Anticoagulants Test-Product Description 22

Table 35: Cascade Abrazo-Direct Thrombin Inhibitors-Product Status 22

Table 36: Cascade Abrazo-Direct Thrombin Inhibitors-Product Description 22

Table 37: Cascade Abrazo-Fibrinogen-Product Status 23

Table 38: Cascade Abrazo-Fibrinogen-Product Description 23

Table 39: Cascade Abrazo-Heparin Titration-Product Status 23

Table 40: Cascade Abrazo-Heparin Titration-Product Description 24

Table 41: Cascade Abrazo-LMWH-Product Status 24

Table 42: Cascade Abrazo-LMWH-Product Description 24

Table 43: Cascade Abrazo-Protamine Titration-Product Status 25

Table 44: Cascade Abrazo-Protamine Titration-Product Description 25

Table 45: Cascade Abrazo-PT-C-Product Status 25

Table 46: Cascade Abrazo-PT-C-Product Description 26

Table 47: Radiometer Medical ApS Pipeline Products & Ongoing Clinical Trials Overview 27

Table 48: AQT90 FLEX-APTT Test-Product Status 27

Table 49: AQT90 FLEX-APTT Test-Product Description 27

Table 50: AQT90 FLEX-PT-INR Test-Product Status 28

Table 51: AQT90 FLEX-PT-INR Test-Product Description 28

Table 52: Universal Biosensors Inc Pipeline Products & Ongoing Clinical Trials Overview 29

Table 53: Diagnostic Assay-Coagulation-Product Status 29

Table 54: Diagnostic Assay-Coagulation-Product Description 29

Table 55: Glossary 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Alere Inc, Afinion PT Test - Capillary Blood; Atomo Diagnostics Pty Limited, AtomoRapid - Coagulation Monitoring; Carclo Diagnostic Solutions Ltd, Micropoc-CAT - Haemostasis Assay; Cascade Metrix LLC, Multiple Blood Analytes Test; Edan Instruments Inc, i15 - Coagulation Test; EKF Diagnostics Holdings Plc, Point-Of-Care Test - Coagulation; Helena Laboratories Corp, Cascade Abrazo - Activated Partial Thromboplastin Time (aPTT); Helena Laboratories Corp, Cascade Abrazo - c-ACT; Helena Laboratories Corp, Cascade Abrazo - c-ACT-LR; Helena Laboratories Corp, Cascade Abrazo - Direct Oral Anticoagulants Test; Helena Laboratories Corp, Cascade Abrazo - Direct Thrombin Inhibitors; Helena Laboratories Corp, Cascade Abrazo - Fibrinogen; Helena Laboratories Corp, Cascade Abrazo - Heparin Titration; Helena Laboratories Corp, Cascade Abrazo - LMWH; Helena Laboratories Corp, Cascade Abrazo - Protamine Titration; Helena Laboratories Corp, Cascade Abrazo - PT-C; Radiometer Medical ApS, AQT90 FLEX - APTT Test; Radiometer Medical ApS, AQT90 FLEX - PT-INR Test; Universal Biosensors Inc, Diagnostic Assay - Coagulation


Companies

Alere Inc

Atomo Diagnostics Pty Limited

Carclo Diagnostic Solutions Ltd

Cascade Metrix LLC

Edan Instruments Inc

EKF Diagnostics Holdings Plc

Helena Laboratories Corp

Radiometer Medical ApS

Universal Biosensors Inc